1. Pink Sheet

Santhera Pulls EU Filing For Failed DMD Candidate

End Of Road For Company’s DMD Idebenone Hopes, Patients 'Devastated'

 
• By Maureen Kenny

Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.

Link between genetics and various dystrophy disorders
DMD is one of the most common and severe forms of muscular dystrophy • Source: Shutterstock

Santhera Pharmaceuticals has formally withdrawn its marketing authorization application (MAA) for idebenone following its recent decision to end the global program under which it was developing the drug as a potential treatment for the rare disease of Duchenne muscular dystrophy (DMD). 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography